Preferred Label : pyrimidines;

Obsolete resource : false;

MeSH definition : A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.;

Wikipedia automatic translation : Pyrimidine;

Wikipedia link : https://en.wikipedia.org/wiki/Pyrimidine;

Codes EINECS : 206-026-0;

Is substance : O;

Details


Main resources

You can consult :

A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.

https://ansm.sante.fr/tableau-atu-rtu/sotorasib-120-mg-comprimes-pellicules
2023
false
false
false
France
French
administration, oral
guidelines for drug use
sotorasib
sotorasib
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
bronchial neoplasms
bronchial neoplasms
summary of product characteristics
package leaflet
adult
neoplasm metastasis
sotorasib
piperazines
pyridines
pyrimidines
piperazines
pyridines
pyrimidines

---
https://presse.inserm.fr/un-nouveau-traitement-entre-en-essai-clinique-chez-un-premier-enfant-achondroplase-en-france/42645
2021
false
false
false
France
French
scientific and technical information
achondroplasia
clinical trials as topic
child
france
Infigratinib
phenylurea compounds
pyrimidines
receptor, fibroblast growth factor, type 1
infigratinib

---
https://www.ema.europa.eu/en/medicines/human/EPAR/evrysdi
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Risdiplam
Risdiplam
drug approval
europe
administration, oral
muscular atrophy, spinal
child
neuromuscular agents
neuromuscular agents
orphan drug production
risdiplam
drug monitoring
infant
adolescent
adult
pregnancy
breast feeding
drug interactions
fertility
Female of Childbearing Potential
drug evaluation, preclinical
azo compounds
pyrimidines
azo compounds
pyrimidines

---
https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medeffet-canada/infovigilance-produits-sante/juillet-2021.html#a6
2021
false
false
false
Canada
French
drug information
canada
Product containing precisely pralsetinib 100 milligram/1 each conventional release oral capsule (clinical drug)
pralsetinib
lung neoplasms
pralsetinib
pyrazoles
pyridines
pyrimidines

---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/nom-commercial-a-venir-5707.html
2021
false
false
false
Canada
French
administration, oral
quebec
muscular atrophy, spinal
Risdiplam
Risdiplam
risdiplam
drug evaluation
rare diseases
child
infant
orphan drug production
azo compounds
pyrimidines
azo compounds
pyrimidines

---
https://ansm.sante.fr/informations-de-securite/xeljanz-tofacitinib-augmentation-du-risque-devenements-cardiovasculaires-indesirables-majeurs-et-de-tumeurs-malignes-avec-lutilisation-de-tofacitinib-en-comparaison-aux-antitnf-alpha
2021
false
false
false
France
French
pharmacovigilance note
tofacitinib
cardiovascular diseases
risk
neoplasms
tofacitinib
tofacitinib
arthritis, rheumatoid
major adverse cardiovascular events
pyrimidines
pyrroles
piperidines
pyrimidines
pyrroles
piperidines

---
https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medeffet-canada/infovigilance-produits-sante/juin-2021.html#a5.4
2021
false
false
false
Canada
French
English
drug approval
canada
drug information
tepotinib
administration, oral
adult
carcinoma, non-small-cell lung
c-Met Inhibitor
protein kinase inhibitors
tepotinib
neoplasm metastasis
piperidines
pyridazines
pyrimidines

---
https://www.has-sante.fr/jcms/p_3240237/fr/imbruvica-leucemie-lymphoide-chronique-llc
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
ibrutinib
ibrutinib
ibrutinib
guidelines for drug use
leukemia, lymphocytic, chronic, B-Cell
antineoplastic combined chemotherapy protocols
Rituximab
Ibrutinib/Rituximab Regimen
administration, oral
antineoplastic agents
antineoplastic agents
adult
survival analysis
evaluation of the transparency committee
ibrutinib
ibrutinib
pyrazoles
pyrimidines
pyrazoles
pyrimidines

---
https://www.has-sante.fr/jcms/p_3244195/fr/zykadia-cbnpc
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
antineoplastic agents
protein kinase inhibitors
receptor Protein-Tyrosine kinases
ceritinib
administration, oral
bronchial neoplasms
carcinoma, non-small-cell lung
ALK gene rearrangement positive
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
ceritinib
pyrimidines
sulfones
pyrimidines
sulfones

---
https://ansm.sante.fr/informations-de-securite/xeljanz-tofacitinib-les-resultats-preliminaires-dun-essai-clinique-indiquent-une-augmentation-du-risque-devenements-cardiovasculaires-et-de-tumeurs-malignes-en-comparaison-aux-anti-tnf-alpha
2021
false
false
false
France
French
clinical trials as topic
tofacitinib
neoplasms
cardiovascular diseases
risk
Janus Kinase Inhibitors
arthritis, rheumatoid
tofacitinib
pharmacovigilance note
pyrimidines
pyrroles
piperidines

---
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2021/75315a-fra.php
2021
false
false
false
Canada
French
English
drug information
tofacitinib
neoplasms
heart diseases
arthritis, rheumatoid
arthritis, psoriatic
administration, oral
colitis, ulcerative
pyrimidines
pyrroles
piperidines

---
https://ansm.sante.fr/tableau-atu-rtu/gavreto-100-mg-gelule
2021
false
false
false
France
French
pralsetinib
guidelines for drug use
pralsetinib
pyrazoles
pyridines
pyrimidines

---
https://ansm.sante.fr/tableau-atu-rtu/pemigatinib-4-5-mg-9-mg-et-13-5-mg-comprime
2021
false
false
false
France
French
package leaflet
summary of product characteristics
guidelines for drug use
administration, oral
morpholines
morpholines
pyrimidines
pyrimidines
pyrroles
pyrroles
pemigatinib
cholangiocarcinoma
adult
Locally Advanced Cholangiocarcinoma
Metastatic Cholangiocarcinoma
cholangiocarcinoma
receptor, fibroblast growth factor, type 2
gene rearrangement
gene fusion
recurrence
Recurrent Cholangiocarcinoma
Refractory Cholangiocarcinoma
receptor, fibroblast growth factor, type 2
FGFR Inhibitor
Tyrosine Kinase Inhibitors
pemigatinib
pemigatinib

---
https://ansm.sante.fr/tableau-atu-rtu/risdiplam-0-75-mg-ml-poudre-pour-solution-buvable
2021
false
false
false
France
French
package leaflet
summary of product characteristics
guidelines for drug use
risdiplam
azo compounds
azo compounds
pyrimidines
pyrimidines
administration, oral
neuromuscular agents
neuromuscular agents
5q spinal muscular atrophy
infant
child
spinal muscular atrophies of childhood
Product containing precisely risdiplam 750 microgram/1 milliliter conventional release oral solution (clinical drug)
Risdiplam
Risdiplam

---
https://cadth.ca/fr/risdiplam
2021
false
false
false
Canada
French
drug information
Risdiplam
azo compounds
pyrimidines

---
https://ansm.sante.fr/uploads/2020/10/30/20201030-dhpc-xeljanz.pdf
2020
false
false
false
France
French
tofacitinib
guidelines for drug use
administration, oral
protein kinase inhibitors
protein kinase inhibitors
risk factors
thrombosis
embolism and thrombosis
Drug-Related side effects and adverse reactions
tofacitinib
arthritis, rheumatoid
arthritis, psoriatic
colitis, ulcerative
venous thromboembolism
tofacitinib
pyrimidines
pyrroles
piperidines
pyrimidines
pyrroles
piperidines

---
https://www.has-sante.fr/jcms/p_3222368/fr/adempas
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
riociguat
hypertension, pulmonary
evaluation of the transparency committee
riociguat
pyrazoles
pyrimidines

---
https://www.has-sante.fr/jcms/p_3210936/fr/adempas
2020
false
false
false
France
riociguat
insurance, health, reimbursement
adult
hypertension, pulmonary
Chronic thromboembolic pulmonary hypertension
thromboembolism
evaluation of the transparency committee
riociguat
pyrazoles
pyrimidines

---
https://www.has-sante.fr/jcms/p_3201262/fr/alunbrig
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
brigatinib
carcinoma, non-small-cell lung
ALK Inhibitor
Anaplastic Lymphoma Kinase
antineoplastic agents
protein kinase inhibitors
adult
brigatinib
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
brigatinib
organophosphorus compounds
pyrimidines

---
https://www.has-sante.fr/jcms/p_3193768/fr/vitrakvi
2020
false
false
false
France
larotrectinib
insurance, health, reimbursement
child
Infantile Fibrosarcoma
fibrosarcoma
sarcoma
neoplasm metastasis
treatment outcome
adult
administration, oral
protein kinase inhibitors
Product containing only larotrectinib in oral dose form (medicinal product form)
evaluation of the transparency committee
larotrectinib
pyrazoles
pyrimidines

---
https://www.has-sante.fr/jcms/p_3181104/fr/imbruvica
2020
false
false
false
France
adult
insurance, health, reimbursement
treatment outcome
drug therapy, combination
Rituximab
waldenstrom macroglobulinemia
ibrutinib
ibrutinib
administration, oral
protein kinase inhibitors
evaluation of the transparency committee
ibrutinib
pyrazoles
pyrimidines

---
https://www.has-sante.fr/jcms/p_3118709/fr/votrient
2019
false
false
false
France
pazopanib
adult
carcinoma, renal cell
sarcoma
Soft Tissue Sarcoma
protein kinase inhibitors
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
pazopanib
pyrimidines
sulfonamides

---
http://www.cri-net.com/ckfinder/userfiles/files/fiches-pratiques/JAKI-octobre2019/JAK_09_Digestif_Hepatiq_MAJ_220719.pdf
2019
false
false
false
France
Janus Kinase Inhibitors
hepatic insufficiency
hepatitis B
hepatitis C
tofacitinib
baricitinib
Alanine aminotransferase outside reference range (finding)
transaminases
intestinal perforation
arthritis, rheumatoid
guideline
pyrimidines
pyrroles
piperidines
azetidines
sulfonamides

---
http://www.cri-net.com/ckfinder/userfiles/files/fiches-pratiques/JAKI-octobre2019/JAK_06_%20Cardio_MAJ_220719.pdf
2019
false
false
false
France
Janus Kinase Inhibitors
cardiovascular agents
anticoagulants
tofacitinib
baricitinib
cholesterol
Janus Kinase Inhibitors
risk
risk factors
drug interactions
guideline
arthritis, rheumatoid
cardiovascular diseases
pyrimidines
pyrroles
piperidines
azetidines
sulfonamides

---
http://www.cri-net.com/ckfinder/userfiles/files/fiches-pratiques/JAKI-octobre2019/JAK_18_Spondyloarthrites_MAJ_220719.pdf
2019
false
false
false
France
adult
tofacitinib
tofacitinib
administration, oral
baricitinib
baricitinib
spondylitis, ankylosing
arthritis, psoriatic
guideline
Janus Kinase Inhibitors
spondylarthropathies
pyrimidines
pyrroles
piperidines
azetidines
sulfonamides

---
http://www.cri-net.com/ckfinder/userfiles/files/fiches-pratiques/JAKI-octobre2019/JAK_07_Cancer_MAJ_220719.pdf
2019
false
false
false
France
neoplasms
risk
Janus Kinase Inhibitors
Janus Kinase Inhibitors
tofacitinib
baricitinib
guideline
arthritis, rheumatoid
pyrimidines
pyrroles
piperidines
azetidines
sulfonamides

---
http://www.cri-net.com/ckfinder/userfiles/files/fiches-pratiques/JAKI-octobre2019/JAK_08_Aff%20Hemato_MAJ_200819.pdf
2019
false
false
false
France
Janus Kinase Inhibitors
baricitinib
tofacitinib
Janus Kinase Inhibitors
risk factors
blood cell count
continuity of patient care
neutropenia
lymphopenia
anemia
algorithms
guideline
hematologic diseases
lymphoma
arthritis, rheumatoid
azetidines
sulfonamides
pyrimidines
pyrroles
piperidines

---
https://www.has-sante.fr/jcms/p_3118131/fr/alunbrig
2019
false
false
false
France
brigatinib
brigatinib
adult
treatment outcome
insurance, health, reimbursement
antineoplastic agents
carcinoma, non-small-cell lung
administration, oral
bronchial neoplasms
evaluation of the transparency committee
brigatinib
organophosphorus compounds
pyrimidines

---
https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-VEGFR-axitinib-cabozantinib-pazopanib-sorafenib-sunitinib
2019
false
false
false
France
Axitinib
cabozantinib
pazopanib
Sorafenib
Sunitinib
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
risk factors
patient education as topic
continuity of patient care
administration, oral
receptors, vascular endothelial growth factor
carcinoma, renal cell
drug interactions
pregnancy
Tyrosine Kinase Inhibitors
guidelines for drug use
Sorafenib
pazopanib
Axitinib
Sunitinib
cabozantinib
pyrimidines
sulfonamides
anilides
pyridines
pyrimidines
sulfonamides
anilides
pyridines
anilides
pyridines
pyrimidines
sulfonamides

---
https://www.ema.europa.eu/en/medicines/human/EPAR/vitrakvi
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
antineoplastic agents
antineoplastic agents
administration, oral
adult
neoplasms
neoplasms
product surveillance, postmarketing
child
gene fusion
receptor, trka
receptor, trkb
receptor, trkc
adolescent
aged
drug interactions
pregnancy
breast feeding
receptor, trka
receptor, trkb
receptor, trkc
protein kinase inhibitors
protein kinase inhibitors
drug evaluation, preclinical
larotrectinib
Tyrosine Kinase Inhibitors
larotrectinib
larotrectinib
pyrazoles
pyrimidines
pyrazoles
pyrimidines

---
https://www.has-sante.fr/jcms/p_3103874/fr/votrient
2019
false
false
false
France
sarcoma
Soft Tissue Sarcoma
treatment outcome
survival analysis
pazopanib
protein kinase inhibitors
protein-tyrosine kinases
adult
pazopanib
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
pazopanib
pyrimidines
sulfonamides
pyrimidines
sulfonamides

---
https://www.has-sante.fr/jcms/c_2912419/fr/xeljanz
2019
false
false
false
France
administration, oral
treatment outcome
insurance, health, reimbursement
tofacitinib
tofacitinib citrate
colitis, ulcerative
protein kinase inhibitors
janus kinases
adult
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
tofacitinib
pyrimidines
pyrroles
piperidines

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00414
2019
false
false
false
Canada
French
drug information
drug approval
canada
telotristat etiprate
telotristat etiprate
telotristat
telotristat
treatment outcome
administration, oral
tryptophan hydroxylase
adult
aged
diarrhea
malignant carcinoid syndrome
telotristat
drug therapy, combination
phenylalanine
phenylalanine
pyrimidines
phenylalanine
pyrimidines

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00426
2019
false
false
false
Canada
French
drug information
drug approval
canada
treatment outcome
elagolix
elagolix
administration, oral
endometriosis
pain
Endometriosis related pain
adult
hydrocarbons, fluorinated
pyrimidines
hydrocarbons, fluorinated
pyrimidines

---
https://www.ansm.sante.fr/actualites/restriction-dutilisation-du-xeljanz-tofacitinib
2019
false
false
false
France
French
guidelines for drug use
tofacitinib
protein kinase inhibitors
arthritis, rheumatoid
arthritis, psoriatic
colitis, ulcerative
administration, oral
tofacitinib
pulmonary embolism
tofacitinib
protein kinase inhibitors
pyrimidines
pyrroles
piperidines
pyrimidines
pyrroles
piperidines

---
https://ansm.sante.fr/informations-de-securite/xeljanz-tofacitinib-ne-plus-prescrire-10-mg-deux-fois-par-jour-chez-les-patients-ayant-un-risque-eleve-dembolie-pulmonaire
2019
false
false
false
France
French
administration, oral
tofacitinib
pharmacovigilance note
guidelines for drug use
pulmonary embolism
risk
arthritis, rheumatoid
tofacitinib
risk assessment
risk factors
tofacitinib
colitis, ulcerative
pyrimidines
pyrroles
piperidines
pyrimidines
pyrroles
piperidines

---
https://www.ansm.sante.fr/actualites/xeljanz-tofacitinib-lansm-demande-aux-professionnels-de-sante-et-aux-patients-de-bien-respecter-la-dose-autorisee-dans-le-traitement-de-la-polyarthrite-rhumatoide
2019
false
false
false
France
French
administration, oral
pharmacovigilance note
tofacitinib citrate
arthritis, rheumatoid
pulmonary embolism
tofacitinib citrate
tofacitinib
risk factors
tofacitinib
tofacitinib
pyrimidines
pyrroles
piperidines
pyrimidines
pyrroles
piperidines

---
Clinical trial finds an increased risk of blood clots in the lungs and of death in rheumatoid arthritis patients taking high dose of tofacitinib (sold as Xeljanz or Xeljanz XR)
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2019/69336a-fra.php
2019
false
false
false
Canada
French
English
pharmacovigilance note
arthritis, rheumatoid
tofacitinib
administration, oral
tofacitinib
protein kinase inhibitors
tofacitinib
pulmonary embolism
protein kinase inhibitors
pyrimidines
pyrroles
piperidines
pyrimidines
pyrroles
piperidines

---
https://www.has-sante.fr/portail/jcms/c_2900185/fr/xermelo
https://www.has-sante.fr/portail/jcms/c_2900185/fr/xermelo-telotristat-antidiarrheique
2019
false
true
false
false
France
French
telotristat
insurance, health, reimbursement
treatment outcome
administration, oral
telotristat
drug therapy, combination
adult
diarrhea
malignant carcinoid syndrome
guidelines for drug use
antidiarrheals
orphan drug production
antidiarrheals
antidiarrheals
evaluation of the transparency committee
phenylalanine
phenylalanine
pyrimidines

---
XELJANZ / XELJANZ XR (tofacitinib) - Risk of Thrombosis
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2019/71766a-fra.php
2019
false
false
false
Canada
French
English
tofacitinib
thrombosis
risk
pharmacovigilance note
tofacitinib
pulmonary embolism
deep vein thrombosis
guidelines for drug use
arthritis, rheumatoid
arthritis, psoriatic
colitis, ulcerative
risk factors
patients guideline
venous thrombosis
pyrimidines
pyrroles
piperidines

---
https://www.has-sante.fr/portail/jcms/c_2894923/en/xeljanz
2018
false
false
false
France
administration, oral
arthritis, psoriatic
adult
treatment outcome
insurance, health, reimbursement
protein kinase inhibitors
evaluation of the transparency committee
tofacitinib
pyrimidines
pyrroles
piperidines

---
https://www.has-sante.fr/portail/jcms/c_2883466/fr/tasigna
2018
false
true
false
France
nilotinib
treatment outcome
insurance, health, reimbursement
nilotinib
evaluation of the transparency committee
nilotinib hydrochloride hydrate
nilotinib
pyrimidines
nilotinib
pyrimidines

---
https://www.has-sante.fr/portail/jcms/c_2888462/fr/zykadia
2018
false
false
false
France
administration, oral
evaluation of the transparency committee
Zykadia
ceritinib
pyrimidines
sulfones

---
https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
brigatinib
brigatinib
brigatinib
adult
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
mutation
administration, oral
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
drug evaluation, preclinical
Tyrosine Kinase Inhibitors
organophosphorus compounds
pyrimidines
organophosphorus compounds
pyrimidines
receptor Protein-Tyrosine kinases
Anaplastic Lymphoma Kinase

---
http://www.cri-net.com/fiches-pratiques-et-recommandations/prise-en-charge-patients-JAKi
2018
false
false
false
France
continuity of patient care
pregnancy
vaccination
travel
virus diseases
bacterial infections
cardiovascular diseases
neoplasms
lymphoma
digestive system diseases
hematologic diseases
dental care
surgical procedures, operative
tofacitinib
baricitinib
drug therapy, combination
arthritis, rheumatoid
Contraindications, Drug
drug interactions
Evidence-Based medicine
baricitinib
tofacitinib
guidelines for drug use
case management
Janus Kinase Inhibitors
pyrimidines
pyrroles
piperidines
azetidines
sulfonamides

---
https://ansm.sante.fr/informations-de-securite/ceritinib-zykadia-r-150-mg-gelule-nouvelle-posologie-recommandee-dinitiation-du-traitement
2018
false
false
false
France
French
guidelines for drug use
pharmacovigilance note
administration, oral
ceritinib
patient education handout
antineoplastic agents
carcinoma, non-small-cell lung
ceritinib
product surveillance, postmarketing
pyrimidines
sulfones

---
https://www.has-sante.fr/portail/jcms/c_2887771/fr/zykadia
2018
false
false
false
France
evaluation of the transparency committee
Zykadia
ceritinib
pyrimidines
sulfones

---
http://www.has-sante.fr/portail/jcms/c_2746213/fr/imbruvica
http://www.has-sante.fr/portail/jcms/c_2746213/fr/imbruvica-ibrutinib-inhibiteur-de-tyrosine-kinase-de-bruton-btk
2017
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
ibrutinib
ibrutinib
administration, oral
treatment outcome
ibrutinib
adult
protein kinase inhibitors
protein kinase inhibitors
IBtk protein, human
IBtk protein, human
insurance, health, reimbursement
orphan drug production
leukemia, lymphocytic, chronic, B-Cell
ibrutinib
ibrutinib
pyrazoles
pyrimidines
pyrazoles
pyrimidines
carrier proteins
carrier proteins

---
https://www.has-sante.fr/portail/jcms/c_2798163/fr/xeljanz-tofacitinib-anti-jak-1-et-3
https://www.has-sante.fr/portail/jcms/c_2798163/fr/xeljanz
2017
false
false
false
France
French
tofacitinib
treatment outcome
tofacitinib
adult
arthritis, rheumatoid
drug therapy, combination
methotrexate
administration, oral
continuity of patient care
protein kinase inhibitors
protein kinase inhibitors
aged
Product containing tofacitinib (medicinal product)
Tofacitinib 5mg tablet (product)
guidelines for drug use
evaluation of the transparency committee
janus kinase 1
janus kinase 3
insurance, health, reimbursement
risk
Tyrosine Kinase Inhibitors
tofacitinib
pyrimidines
pyrroles
piperidines
pyrimidines
pyrroles
piperidines

---
https://www.ema.europa.eu/medicines/human/EPAR/Xeljanz
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
tofacitinib
drug approval
europe
treatment outcome
tofacitinib
adult
arthritis, rheumatoid
drug therapy, combination
methotrexate
administration, oral
continuity of patient care
drug monitoring
janus kinases
pregnancy
breast feeding
drug interactions
protein kinase inhibitors
protein kinase inhibitors
product surveillance, postmarketing
aged
drug evaluation, preclinical
Product containing tofacitinib (medicinal product)
Tofacitinib 5mg tablet (product)
Tyrosine Kinase Inhibitors
tofacitinib
pyrimidines
pyrroles
piperidines
pyrimidines
pyrroles
piperidines

---
https://www.has-sante.fr/portail/jcms/c_2824816/fr/zykadia
https://www.has-sante.fr/portail/jcms/c_2824816/fr/zykadia-ceritinib-inhibiteur-de-tyrosine-kinase
2017
false
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
administration, oral
ceritinib
ceritinib
ceritinib
adult
Advanced Malignant Neoplasm
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
ALK gene rearrangement positive
insurance, health, reimbursement
protein kinase inhibitors
protein kinase inhibitors
antineoplastic agents
antineoplastic agents
protein-tyrosine kinases
survival analysis
guidelines for drug use
Tyrosine Kinase Inhibitors
pyrimidines
sulfones
pyrimidines
sulfones
receptor Protein-Tyrosine kinases
Anaplastic Lymphoma Kinase

---
http://www.prescrire.org/Fr/3/31/53068/0/NewsDetails.aspx
2017
false
false
false
France
French
french abstract
leukaemia
leukemia, lymphocytic, chronic, B-Cell
leukemia, lymphoid
chronic lymphocytic leukemia
ibrutinib
widening, nos
ibrutinib
leukemia, lymphoid
ibrutinib
pyrazoles
pyrimidines

---
https://www.has-sante.fr/portail/jcms/c_2770187/fr/imbruvica-lcm
https://www.has-sante.fr/portail/jcms/c_2770187/fr/imbruvica-ibrutinib-inhibiteur-de-tyrosine-kinase-de-bruton-btk-lcm
2017
false
false
false
false
France
French
evaluation of the transparency committee
administration, oral
insurance, health, reimbursement
treatment outcome
ibrutinib
ibrutinib
orphan drug production
ibrutinib
adult
Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma
lymphoma, mantle-cell
IBtk protein, human
protein-tyrosine kinases
protein kinase inhibitors
protein kinase inhibitors
survival analysis
comparative effectiveness research
temsirolimus
guidelines for drug use
Progression-Free survival
Tyrosine Kinase Inhibitors
ibrutinib
ibrutinib
carrier proteins
pyrazoles
pyrimidines
pyrazoles
pyrimidines
sirolimus
sirolimus
disease-free survival

---
In : Bulletin du Cancer Volume 103, Issue 2, February 2016, Pages 180–189 - Open Access
http://www.sciencedirect.com/science/article/pii/S0007455115003689
2016
false
false
false
Netherlands
French
journal article
nilotinib
nilotinib
protein-tyrosine kinases
leukemia, myeloid, chronic-phase
cardiovascular diseases
risk factors
risk assessment
cardiovascular diseases
practice guideline
Tyrosine Kinase Inhibitors
nilotinib
nilotinib
pyrimidines
pyrimidines

---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-BCR-ABL-Imatinib-Dasatinib-Nilotinib-Bosutinib-Ponatinib-Medicament-ciblant-JAK-Ruxolitinib-Anticancereux-par-voie-orale-informer-prevenir-et-gerer-leurs-effets-indesirables
2016
false
false
false
France
French
practice guideline
antineoplastic agents
administration, oral
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
information dissemination
patient education as topic
drug interactions
Dasatinib
Imatinib Mesylate
fusion proteins, bcr-abl
protein kinase inhibitors
dasatinib
imatinib
nilotinib
nilotinib
bosutinib
ponatinib
ruxolitinib
janus kinases
ponatinib
ruxolitinib
bosutinib
continuity of patient care
pregnancy
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
aniline compounds
nitriles
quinolines
imidazoles
pyridazines
pyrimidines
pyrazoles

---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-ALK-crizotinib-ceritinib
2016
false
false
false
France
French
guidelines for drug use
protein kinase inhibitors
crizotinib
carcinoma, non-small-cell lung
ceritinib
ceritinib
receptor Protein-Tyrosine kinases
antineoplastic agents
administration, oral
protein kinase inhibitors
ceritinib
Drug-Related side effects and adverse reactions
continuity of patient care
drug interactions
interdisciplinary communication
risk factors
drug monitoring
ceritinib
carcinoma, non-small-cell lung
ALK gene rearrangement positive
ALK protein, human
patients guideline
practice guideline
Tyrosine Kinase Inhibitors
pyrimidines
sulfones
pyrimidines
sulfones
pyrimidines
sulfones
receptor Protein-Tyrosine kinases
Crizotinib
Crizotinib
Crizotinib
Anaplastic Lymphoma Kinase

---
ADEMPAS (riociguat) - New Contraindication for Patients with Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonias (PH-IIP)
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/59816a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
hypertension, pulmonary
riociguat
riociguat
administration, oral
idiopathic interstitial pneumonias
Contraindications, Procedure
pyrazoles
pyrimidines
Contraindications, Drug

---
http://www.has-sante.fr/portail/jcms/c_2678886/fr/trevicta
http://www.has-sante.fr/portail/jcms/c_2678886/fr/trevicta-paliperidone-antipsychotique
2016
false
France
French
insurance, health, reimbursement
evaluation of the transparency committee
guidelines for drug use
Every Three Months
Delayed-Action preparations
injections, intramuscular
aged
treatment outcome
antipsychotic agents
antipsychotic agents
paliperidone
adult
schizophrenia
Paliperidone Palmitate
Paliperidone Palmitate
isoxazoles
pyrimidines
isoxazoles
pyrimidines

---
http://www.has-sante.fr/portail/jcms/c_2742289/fr/imbruvica
http://www.has-sante.fr/portail/jcms/c_2742289/fr/imbruvica-ibrutinib-inhibiteur-de-tyrosine-kinase-de-bruton-btk
2016
false
false
false
false
France
French
evaluation of the transparency committee
administration, oral
insurance, health, reimbursement
treatment outcome
ibrutinib
ibrutinib
ibrutinib
adult
IBtk protein, human
protein-tyrosine kinases
protein kinase inhibitors
protein kinase inhibitors
waldenstrom macroglobulinemia
guidelines for drug use
Tyrosine Kinase Inhibitors
ibrutinib
ibrutinib
pyrazoles
pyrimidines
pyrazoles
pyrimidines
carrier proteins

---
BCR-ABL Tyrosine Kinase Inhibitors [GLEEVEC (imatinib mesylate), TASIGNA (nilotinib), BOSULIF (bosutinib), SPRYCEL (dasatinib), ICLUSIG (ponatinib hydrochloride)] - Risk of Hepatitis B Reactivation
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58222a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
fusion proteins, bcr-abl
protein kinase inhibitors
Imatinib Mesylate
risk
hepatitis b virus
imatinib
nilotinib
nilotinib
bosutinib
bosutinib
Dasatinib
dasatinib
ponatinib hydrochloride
ponatinib
Tyrosine Kinase Inhibitor
Hepatitis B reactivation
guidelines for drug use
continuity of patient care
mass screening
hepatitis B
hepatitis B
Tyrosine Kinase Inhibitors
nilotinib
ponatinib
pyrimidines
imidazoles
pyridazines
aniline compounds
nitriles
quinolines

---
http://www.has-sante.fr/portail/jcms/c_2569228/fr/zykadia
http://www.has-sante.fr/portail/jcms/c_2569228/fr/zykadia-ceritinib-inhibiteur-de-tyrosine-kinase
2015
false
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
administration, oral
ceritinib
ceritinib
ceritinib
adult
Advanced Malignant Neoplasm
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
ALK gene rearrangement positive
insurance, health, reimbursement
protein kinase inhibitors
protein kinase inhibitors
antineoplastic agents
antineoplastic agents
protein-tyrosine kinases
survival analysis
guidelines for drug use
Tyrosine Kinase Inhibitors
pyrimidines
sulfones
pyrimidines
sulfones
receptor Protein-Tyrosine kinases
Anaplastic Lymphoma Kinase

---
http://www.has-sante.fr/portail/jcms/c_2049868/fr/imbruvica
http://www.has-sante.fr/portail/jcms/c_2049868/fr/imbruvica-ibrutinib-inhibiteur-de-tyrosine-kinase-de-bruton-btk
2015
false
false
false
France
French
evaluation of the transparency committee
administration, oral
insurance, health, reimbursement
treatment outcome
ibrutinib
ibrutinib
orphan drug production
ibrutinib
adult
Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma
lymphoma, mantle-cell
leukemia, lymphocytic, chronic, B-Cell
leukemia, lymphocytic, chronic, B-Cell
IBtk protein, human
protein-tyrosine kinases
protein kinase inhibitors
protein kinase inhibitors
survival analysis
guidelines for drug use
Tyrosine Kinase Inhibitors
ibrutinib
ibrutinib
carrier proteins
pyrazoles
pyrimidines
pyrazoles
pyrimidines

---
https://www.ema.europa.eu/medicines/human/EPAR/Zykadia
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
ceritinib
drug approval
europe
pyrimidines
pyrimidines
sulfones
sulfones
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
receptor Protein-Tyrosine kinases
adult
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
administration, oral
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
ceritinib
ceritinib
Tyrosine Kinase Inhibitors
Anaplastic Lymphoma Kinase

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=63012197
2015
false
false
false
France
French
summary of product characteristics
package leaflet
ibrutinib
capsules
ibrutinib
ibrutinib
pyrazoles
pyrimidines

---
http://www.has-sante.fr/portail/jcms/c_2583127/fr/opsumit
http://www.has-sante.fr/portail/jcms/c_2583127/fr/opsumit-macitentan-antagonistes-des-recepteurs-de-l-endotheline
2015
false
false
false
France
French
evaluation of the transparency committee
macitentan
hypertension, pulmonary
adult
administration, oral
macitentan
treatment outcome
drug therapy, combination
idiopathic pulmonary arterial hypertension
Pulmonary arterial hypertension associated with connective tissue disease
Pulmonary arterial hypertension associated with congenital heart disease
orphan drug production
Endothelin A Receptor Antagonists
Endothelin B Receptor Antagonists
Familial Primary Pulmonary Hypertension
guidelines for drug use
Product containing macitentan in oral dose form (medicinal product form)
pyrimidines
sulfonamides

---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=144345&nom=Pyrimidine
Canada
toxicological data sheet
pyrimidines
pyrimidine

---
https://www.ema.europa.eu/medicines/human/EPAR/Opsumit
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
macitentan
macitentan
macitentan
orphan drug production
hypertension, pulmonary
adult
administration, oral
product surveillance, postmarketing
continuity of patient care
drug monitoring
aged
drug interactions
pregnancy
breast feeding
fertility
contraception
reproduction
clinical trials, phase iii as topic
drug evaluation, preclinical
Endothelin A Receptor Antagonists
Endothelin B Receptor Antagonists
Endothelin A Receptor Antagonists
Endothelin B Receptor Antagonists
Product containing macitentan in oral dose form (medicinal product form)
pyrimidines
sulfonamides
pyrimidines
sulfonamides

---
http://www.meddispar.fr/Medicaments/VOTRIENT-400-B-30/(type)/letter/(value)/V/(cip)/3400949131570
http://www.meddispar.fr/Medicaments/VOTRIENT-400-B-60/%28type%29/letter/%28value%29/V/%28cip%29/3400949131631
2014
false
false
false
drug information
administration, oral
drug prescriptions
legislation, drug
continuity of patient care
pazopanib
pazopanib
pyrimidines
sulfonamides

---
http://www.meddispar.fr/Medicaments/VOTRIENT-200-B-30/(type)/letter/(value)/V/(cip)/3400949131341
2014
false
false
false
drug information
administration, oral
drug prescriptions
legislation, drug
pazopanib
pazopanib
continuity of patient care
pyrimidines
sulfonamides

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=61875550
2014
false
false
false
France
French
summary of product characteristics
pill, nos
dandruff
tablets
riociguat
compression, nos
seborrhea sicca
riociguat
riociguat
dandruff
pyrazoles
pyrimidines

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=60203795
2014
false
false
false
France
French
summary of product characteristics
dandruff
riociguat
compression, nos
seborrhea sicca
riociguat
riociguat
tablets
pill, nos
dandruff
pyrazoles
pyrimidines

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=60025054
2014
false
false
false
France
French
summary of product characteristics
seborrhea sicca
riociguat
riociguat
pill, nos
dandruff
riociguat
compression, nos
tablets
dandruff
pyrazoles
pyrimidines

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=66086562
2014
false
false
false
France
French
summary of product characteristics
tablets
riociguat
seborrhea sicca
riociguat
compression, nos
riociguat
dandruff
pill, nos
dandruff
pyrazoles
pyrimidines

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=64832942
2014
false
false
false
France
French
summary of product characteristics
seborrhea sicca
riociguat
riociguat
pill, nos
dandruff
tablets
riociguat
compression, nos
dandruff
pyrazoles
pyrimidines

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=63294049
2014
false
false
false
France
French
summary of product characteristics
package leaflet
avanafil
pill, nos
avanafil
compression, nos
tablets
avanafil
pyrimidines

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=66839572
2014
false
false
false
France
French
summary of product characteristics
package leaflet
avanafil
pill, nos
avanafil
compression, nos
avanafil
tablets
pyrimidines

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=68366495
2014
false
false
false
France
French
summary of product characteristics
package leaflet
avanafil
avanafil
pill, nos
avanafil
compression, nos
tablets
pyrimidines

---
http://www.has-sante.fr/portail/jcms/c_1761611/fr/adempas
2014
false
false
false
France
French
evaluation of the transparency committee
administration, oral
riociguat
hypertension, pulmonary
adult
drug therapy, combination
treatment outcome
Chronic thromboembolic pulmonary hypertension
orphan drug production
riociguat
guidelines for drug use
riociguat
pyrazoles
pyrimidines
pyrazoles
pyrimidines

---
http://www.has-sante.fr/portail/jcms/c_1769783/fr/opsumit
2014
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
macitentan
macitentan
hypertension, pulmonary
adult
administration, oral
macitentan
treatment outcome
drug therapy, combination
idiopathic pulmonary arterial hypertension
Pulmonary arterial hypertension associated with connective tissue disease
Pulmonary arterial hypertension associated with congenital heart disease
orphan drug production
Endothelin A Receptor Antagonists
Endothelin B Receptor Antagonists
Endothelin A Receptor Antagonists
Endothelin B Receptor Antagonists
Familial Primary Pulmonary Hypertension
Product containing macitentan in oral dose form (medicinal product form)
pyrimidines
sulfonamides
pyrimidines
sulfonamides

---
https://www.ema.europa.eu/medicines/human/EPAR/Imbruvica
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
ibrutinib
ibrutinib
drug approval
europe
antineoplastic agents
antineoplastic agents
orphan drug production
leukemia, lymphocytic, chronic, B-Cell
lymphoma, mantle-cell
ibrutinib
leukemia, lymphocytic, chronic, B-Cell
administration, oral
capsules
IBtk protein, human
protein kinase inhibitors
protein kinase inhibitors
drug monitoring
continuity of patient care
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
ibrutinib
ibrutinib
pyrazoles
pyrimidines
pyrazoles
pyrimidines
carrier proteins

---
https://www.revmed.ch/RMS/2014/RMS-N-414/Rhumatologie-Une-nouvelle-option-therapeutique-dans-la-prise-en-charge-de-l-inflammation-chronique-en-rhumatologie-les-inhibiteurs-des-Janus-kinases
2014
false
false
false
Switzerland
piperidines
journal article
tofacitinib
protein kinase inhibitors
pyrimidines
pyrroles
tofacitinib
protein kinase inhibitors
piperidines
pyrimidines
pyrroles
arthritis, rheumatoid

---
https://www.ema.europa.eu/medicines/human/EPAR/Tasigna
2012
false
United Kingdom
French
English
syndication feed
Tyrosine Kinase Inhibitors
fusion proteins, bcr-abl
pyrimidines
leukemia, myelogenous, chronic, bcr-abl positive
protein kinase inhibitors
pyrimidines
protein kinase inhibitors
orphan drug production
capsules
administration, oral
adult
drug evaluation
treatment outcome
drug approval
drug labeling
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
antineoplastic agents
antineoplastic agents
nilotinib
nilotinib
nilotinib
drug evaluation
summary of product characteristics
package leaflet

---
http://www.meddispar.fr/Medicaments/TASIGNA-150-B-28/(type)/letter/(value)/T/(cip)/3400949815845
http://www.meddispar.fr/Medicaments/TASIGNA-150-B-112/(type)/letter/(value)/T/(cip)/3400949815906
2012
false
France
French
drug prescriptions
capsules
pyrimidines
legislation, drug
administration, oral
nilotinib
nilotinib
drug information

---
https://www.ema.europa.eu/medicines/human/EPAR/Sonata
2012
false
United Kingdom
French
English
syndication feed
Product containing precisely zaleplon 10 milligram/1 each conventional release oral capsule (clinical drug)
Product containing precisely zaleplon 5 milligram/1 each conventional release oral capsule (clinical drug)
Contraindications, Procedure
zaleplon
zaleplon
administration, oral
adult
acetamides
pyrimidines
hypnotics and sedatives
pregnancy
breast feeding
aged
acetamides
pyrimidines
hypnotics and sedatives
drug interactions
acetamides
pyrimidines
hypnotics and sedatives
acetamides
pyrimidines
acetamides
acetamides
pyrimidines
hypnotics and sedatives
sleep initiation and maintenance disorders
acetamides
pyrimidines
hypnotics and sedatives
treatment outcome
drug evaluation
drug evaluation, preclinical
capsules
hypnotics and sedatives
pyrimidines
hypnotics and sedatives
acetamides
pyrimidines
hypnotics and sedatives
drug labeling
drug approval
acetamides
pyrimidines
drug evaluation
summary of product characteristics
package leaflet
Contraindications, Drug

---
https://www.ema.europa.eu/medicines/human/EPAR/Invega
2012
false
United Kingdom
French
English
syndication feed
Paliperidone Palmitate
paliperidone
antipsychotic agents
schizophrenia
treatment outcome
drug evaluation
paliperidone
drug evaluation
summary of product characteristics
package leaflet
isoxazoles
pyrimidines

---
http://www.cochrane.org/fr/CD007823
2011
false
true
false
France
United Kingdom
pyrimidines
treatment outcome
review of literature
french abstract
liver neoplasms
colorectal neoplasms
infusions, Intra-Arterial

---
http://www.oncoprof.net/Generale2000/g11_AutresTraitements/g11_at10e.php
2011
false
true
false
France
receptors, vascular endothelial growth factor
pyrimidines
pyrimidines
pyrimidines
pyrimidines
sulfonamides
sulfonamides
sulfonamides
sulfonamides
Tyrosine Kinase Inhibitors
pazopanib

---
http://medecine-pharmacie.univ-rouen.fr/jsp/saisie/liste_fichiergw.jsp?OBJET=DOCUMENT&CODE=1190377229762&LANGUE=0
2009
false
false
France
French
piperazines
medical oncology
pyrimidines
leukemia, myelogenous, chronic, bcr-abl positive
myeloproliferative disorders
educational course

---
http://www.has-sante.fr/portail/jcms/c_854637/glivec-ct-6889
http://www.has-sante.fr/portail/jcms/c_854122/glivec
2009
false
France
French
piperazines
pyrimidines
antibiotics, antineoplastic
imatinib
drug evaluation

---
INVEGA Paliperidone, 3 mg, 6 mg, 9 mg, 12 mg, extended-release tablets Janssen-Ortho Inc - Summary Basis of Decision (SBD)
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00075
2008
false
Canada
English
French
paliperidone
paliperidone
tablets
antipsychotic agents
drug approval
receptor, serotonin, 5-ht2a
dopamine antagonists
receptors, dopamine d2
treatment outcome
schizophrenia
administration, oral
antipsychotic agents
paliperidone
serotonin 5-HT2 receptor antagonists
drug information
package leaflet
Paliperidone Palmitate
Paliperidone Palmitate
isoxazoles
pyrimidines
isoxazoles
pyrimidines

---
https://cadth.ca/sites/default/files/cdr/complete/cdr_complete_Invega%20_May-28-2008_f.pdf
2008
false
Canada
French
paliperidone
antipsychotic agents
schizophrenia
administration, oral
Delayed-Action preparations
insurance, health, reimbursement
canada
tablets
drug costs
paliperidone
drug evaluation
Paliperidone Palmitate
isoxazoles
pyrimidines

---
https://www.jle.com/fr/revues/medecine/bdc/e-docs/00/04/36/1F/article.md
2007
France
French
leukemia, myelogenous, chronic, bcr-abl positive
piperazines
pyrimidines
antineoplastic agents
journal article

---
http://www.has-sante.fr/portail/display.jsp?id=c_627649
2007
false
France
French
paliperidone
antipsychotic agents
schizophrenia
tablets
Delayed-Action preparations
administration, oral
treatment outcome
insurance, health, reimbursement
paliperidone
evaluation of the transparency committee
Paliperidone Palmitate
isoxazoles
pyrimidines

---
Nous contacter.
25/04/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.